This suggests that in clinical practice, for patients with T2DM complicated by hypoechoic plaques, consideration should be given to using medications that target the reduction of VLDL and lower HDL/ApoA1 levels, in order to further reduce their residual risk of ASCVD. Here, APOA1 is linked to type 2 diabetes mellitus.